Daxor Corporation

Daxor Corporation is a medical instrumentation and biotechnology company headquartered in Oak Ridge, Tennessee, specializing in blood volume measurement. The company's mission is to advance healthcare by enabling optimal fluid management through blood volume analysis, aiming for optimal blood volume for all patients.

Daxor's core offering is its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic technology, including the BVA-100 Blood Volume Analyzer and a next-generation rapid, compact, hand-held BVA device. This technology provides precise, real-time data for fluid management in various medical conditions, such as heart failure, critical care, surgical settings, cardiology, nephrology, sepsis, ARDS, and syncope. Daxor also offers an ezBVA Lab service for off-site sample processing and, historically, cryobanking services through subsidiaries.

Led by CEO Michael Feldschuh, Daxor Corporation is recognized as a global leader in blood volume measurement technology. Recent developments include FDA 510(k) clearance for its new rapid BVA system in August 2025 and a strategic transition in regulatory reporting to align with its focus as a diagnostic technology operating business. The company has reported significant revenue growth, expanded its BVA programs into new healthcare centers, and continues to work on next-generation analyzers under contracts with the U.S. Department of Defense.